News | June 03, 2026
Granules Pharmaceuticals receives USFDA EIR for Chantilly facility
This facility plays an important role in Granules’ global manufacturing and supply network
This facility plays an important role in Granules’ global manufacturing and supply network
The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States
The inspection is now closed, and no regulatory action has been recommended
This inspection is now closed
The EIR was issued following an inspection of the facility from November 10 to November 21, 2025
Inspection included drug device combinations covering our recent filing in nasal sprays domain
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
The EIR was issued following an inspection of the facility from September 8 to September 16, 2025
This inspection was conducted following the warning letter issued by the USFDA
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
